CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced updates on the INTERCEPT red blood cell (RBC) programs in the U.S. and in Europe: U.S. – New $248 million BARDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback